EBS · Emergent BioSolutions Inc. · Webcasts, Transcripts & Audio
$5.79
-0.10 (-1.70%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$297.69M
Shares
51.42M
Volume · Nov 13
787.19K
Avg daily vol (3M)
1.13M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Emergent BioSolutions Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Emergent BioSolutions Inc. (EBS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-18
Emergent BioSolutions Inc. (EBS) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-02
Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript
Positive tone
Balance sheet and liquidity
Government medical countermeasures
Revenue and profitability
Revenue
$110.00M
▼ 52.4% YoY Diluted EPS
$-0.64
▼ 170.3% YoY Gross margin
26.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Emergent BioSolutions Inc. (EBS) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Positive tone
Naloxone/Narcan market pressure
MCM / government contracts
International expansion
Revenue
$234.30M
▲ 66.3% YoY Diluted EPS
$-3.49
Gross margin
58.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Emergent BioSolutions Inc. (EBS) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Positive tone
Q1 financial results vs. guidance
Debt reduction and capital allocation
Government contracts and partnerships
Revenue
$156.10M
▼ 29.7% YoY Diluted EPS
$0.07
▼ 94.1% YoY Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Transcript
Confident tone
Financial performance and profitability
Debt reduction and balance sheet
Medical Countermeasures (MCM) / biodefense business
Revenue
$148.70M*
▼ 23.6% YoY Gross margin
42.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript
Confident tone
Biodefense / MCM contract momentum
Government shutdown and macro risk
Financial outperformance and raised guidance
Revenue
$231.10M
▼ 21.3% YoY Diluted EPS
$0.91
▼ 55.8% YoY Gross margin
62.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript
Confident tone
Naloxone / NARCAN franchise
Financial performance and guidance raise
Medical Countermeasures (MCM) and biodefense contracts
Revenue
$140.90M
▼ 44.7% YoY Diluted EPS
$-0.22
Gross margin
52.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Positive tone
Financial performance and guidance
International medical countermeasure growth
NARCAN and naloxone market
Revenue
$222.20M
▼ 26% YoY Diluted EPS
$1.19
▲ 600% YoY Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript
Positive tone
Kloxado acquisition and integration
Medical countermeasures (MCM) government contracts
NARCAN nasal spray and opioid response
Revenue
$194.70M*
▼ 29.6% YoY Gross margin
39.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-02
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript
Positive tone
Revenue and EBITDA guidance
Multi-year turnaround plan
Operational cost reductions and site network
Revenue
$293.80M
▲ 8.6% YoY Diluted EPS
$2.06
Gross margin
54.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
Positive tone
Restructuring and workforce reduction
Manufacturing and margin improvement
NARCAN Nasal Spray growth and access expansion
Revenue
$254.70M
▼ 24.6% YoY Diluted EPS
$-5.38
Gross margin
-18.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Emergent BioSolutions Inc. (EBS) Q1 2024 Earnings Call Transcript
Positive tone
NARCAN
Medical countermeasures (MCM)
Guidance raise
Revenue
$300.40M
▲ 82.8% YoY Diluted EPS
$0.17
Gross margin
49.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Emergent BioSolutions Inc. (EBS) Q4 2023 Earnings Call Transcript
Cautious tone
MCM / government procurement
NARCAN Nasal Spray / opioid crisis
New CEO transition
Revenue
$276.60M*
▼ 16.2% YoY Gross margin
30.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Emergent BioSolutions Inc. (EBS) Q3 2023 Earnings Call Transcript
Revenue
$270.50M
▲ 12.8% YoY Diluted EPS
$-5.08
Gross margin
32.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Emergent BioSolutions Inc. (EBS) Q2 2023 Earnings Call Transcript
Revenue
$337.90M
▲ 39.3% YoY Diluted EPS
$-5.16
Gross margin
41.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Emergent BioSolutions Inc. (EBS) Q1 2023 Earnings Call Transcript
Revenue
$164.30M
▼ 46.1% YoY Diluted EPS
$-3.71
Gross margin
3.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Emergent BioSolutions Inc. (EBS) Q4 2022 Earnings Call Transcript
Revenue
$330.20M
▼ 54.9% YoY Diluted EPS
$-1.34
▼ 137.2% YoY Gross margin
30.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Emergent BioSolutions Inc. (EBS) Q3 2022 Earnings Call Transcript
Revenue
$239.90M
▼ 16.2% YoY Diluted EPS
$-1.75
Gross margin
31.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-01
Emergent BioSolutions Inc. (EBS) Q2 2022 Earnings Call Transcript
Revenue
$242.60M
▼ 35.7% YoY Diluted EPS
$-1.06
Gross margin
27.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Emergent BioSolutions Inc. (EBS) Q1 2022 Earnings Call Transcript
Revenue
$304.80M
▼ 19.2% YoY Diluted EPS
$-0.09
▼ 107.3% YoY Gross margin
46.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Emergent BioSolutions Inc. (EBS) Q4 2021 Earnings Call Transcript
Revenue
$732.90M
▲ 25.7% YoY Diluted EPS
$3.60
▲ 4.7% YoY Gross margin
58.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Emergent BioSolutions Inc. (EBS) Q3 2021 Earnings Call Transcript
Revenue
$286.30M
▼ 25.7% YoY Diluted EPS
$-0.75
▼ 202.7% YoY Gross margin
33.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Emergent BioSolutions Inc. (EBS) Q2 2021 Earnings Call Transcript
Revenue
$377.40M
▼ 4.4% YoY Diluted EPS
$-0.01
▼ 100.6% YoY Gross margin
38.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Emergent BioSolutions Inc. (EBS) Q1 2021 Earnings Call Transcript
Revenue
$377.00M
▲ 95.8% YoY Diluted EPS
$1.23
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Emergent BioSolutions Inc. (EBS) Q4 2020 Earnings Call Transcript
Revenue
$583.00M
▲ 61.8% YoY Diluted EPS
$3.44
▲ 282.2% YoY Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Emergent BioSolutions Inc. (EBS) Q3 2020 Earnings Call Transcript
Revenue
$385.20M
▲ 23.5% YoY Diluted EPS
$0.73
▼ 12% YoY Gross margin
61.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Emergent BioSolutions Inc. (EBS) Q2 2020 Earnings Call Transcript
Revenue
$394.70M
▲ 62.3% YoY Diluted EPS
$1.73
Gross margin
67.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Emergent BioSolutions Inc. (EBS) Q1 2020 Earnings Call Transcript
Revenue
$192.50M
▲ 1% YoY Diluted EPS
$-0.24
Gross margin
60.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Emergent BioSolutions Inc. (EBS) Q4 2019 Earnings Call Transcript
Revenue
$360.40M
▲ 33.1% YoY Diluted EPS
$0.90
Gross margin
63.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY19 · Q3
2019-11-06
Emergent BioSolutions Inc. (EBS) Q3 2019 Earnings Call Transcript
Revenue
$311.80M
▲ 79.5% YoY Diluted EPS
$0.83
▲ 102.4% YoY Gross margin
65.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q2
2019-08-01
Emergent BioSolutions Inc. (EBS) Q2 2019 Earnings Call Transcript
Revenue
$243.20M
▲ 10.4% YoY Diluted EPS
$-0.18
▼ 118.4% YoY Gross margin
58.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q1
2019-05-02
Emergent BioSolutions Inc. (EBS) Q1 2019 Earnings Call Transcript
Revenue
$190.60M
▲ 61.8% YoY Diluted EPS
$-0.51
Gross margin
51.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY18 · Q4
2019-02-21
Emergent BioSolutions Inc. (EBS) Q4 2018 Earnings Call Transcript
Revenue
$270.70M
▲ 39.7% YoY Diluted EPS
$-0.07
Gross margin
58.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY18 · Q3
2018-11-01
Emergent BioSolutions Inc. (EBS) Q3 2018 Earnings Call Transcript
Revenue
$173.70M
▲ 16.3% YoY Diluted EPS
$0.41
▼ 39.7% YoY Gross margin
60.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY18 · Q2
2018-08-02
Emergent BioSolutions Inc. (EBS) Q2 2018 Earnings Call Transcript
Revenue
$220.20M
▲ 118.5% YoY Diluted EPS
$0.98
▲ 790.9% YoY Gross margin
61.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY18 · Q1
2018-05-03
Emergent BioSolutions Inc. (EBS) Q1 2018 Earnings Call Transcript
Revenue
$117.80M
▲ 0.8% YoY Diluted EPS
$-0.10
▼ 143.5% YoY Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY17 · Q4
2018-02-22
Emergent BioSolutions Inc. (EBS) Q4 2017 Earnings Call Transcript
Revenue
$193.80M
▲ 27.8% YoY Gross margin
67.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY17 · Q3
2017-11-02
Emergent BioSolutions Inc. (EBS) Q3 2017 Earnings Call Transcript
Revenue
$149.40M
▲ 4.5% YoY Diluted EPS
$0.68
▲ 51.1% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY17 · Q2
2017-08-03
Emergent BioSolutions Inc. (EBS) Q2 2017 Earnings Call Transcript
Revenue
$100.80M
▲ 10.5% YoY Diluted EPS
$0.11
Gross margin
65.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY17 · Q1
2017-05-04
Emergent BioSolutions Inc. (EBS) Q1 2017 Earnings Call Transcript
Revenue
$116.90M
▲ 5.3% YoY Diluted EPS
$0.23
▲ 130% YoY Gross margin
60.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY16 · Q4
2017-02-23
Emergent BioSolutions Inc. (EBS) Q4 2016 Earnings Call Transcript
Revenue
$151.66M
▼ 5.1% YoY Diluted EPS
$0.77
▲ 8.5% YoY Gross margin
78.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY16 · Q3
2016-11-07
Emergent BioSolutions Inc. (EBS) Q3 2016 Earnings Call Transcript
Revenue
$142.91M
▼ 13.4% YoY Diluted EPS
$0.45
▼ 43% YoY Gross margin
72.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY16 · Q2
2016-06-30
Date not confirmed
Emergent BioSolutions Inc. (EBS) Q2 2016 Earnings Call Transcript
Revenue
$91.24M
▼ 27.7% YoY Diluted EPS
$-0.27
▼ 184.4% YoY Gross margin
67.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY16 · Q1
2016-05-05
Emergent BioSolutions Inc. (EBS) Q1 2016 Earnings Call Transcript
Revenue
$111.00M
▲ 74.4% YoY Diluted EPS
$0.10
Gross margin
78.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY15 · Q4
2016-02-25
Emergent BioSolutions Inc. (EBS) Q4 2015 Earnings Call Transcript
Revenue
$159.78M
▲ 8% YoY Diluted EPS
$0.71
▲ 7.6% YoY Gross margin
40.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY15 · Q3
2015-11-05
Emergent BioSolutions Inc. (EBS) Q3 2015 Earnings Call Transcript
Revenue
$164.94M
▲ 19.6% YoY Diluted EPS
$0.79
▲ 61.2% YoY Gross margin
78.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY15 · Q2
2015-08-06
Emergent BioSolutions Inc. (EBS) Q2 2015 Earnings Call Transcript
Revenue
$126.11M
▲ 14.3% YoY Diluted EPS
$0.32
▲ 146.2% YoY Gross margin
27.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY15 · Q1
2015-05-07
Emergent BioSolutions Inc. (EBS) Q1 2015 Earnings Call Transcript
Revenue
$63.63M
▲ 18.1% YoY Diluted EPS
$-0.57
Gross margin
-34.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–50 of 82 webcasts
Key facts
CIK
1367644
CUSIP
29089Q105
13F (30d)
143 filings
123 filers
Visit website
Investor relations